Research & Development Market Research Reports & Industry Analysis
New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.
Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.
Research & Development Industry Research & Market Reports
-
Cannabis Edibles
... CAGR of 22.0% over the analysis period 2024-2030. Solid Cannabis Edibles, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$38.2 Billion by the end of the ... Read More
-
Male Hypogonadism
... CAGR of 5.1% over the analysis period 2024-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.5 Billion by the end of the ... Read More
-
Medical Marijuana
... CAGR of 14.4% over the analysis period 2024-2030. Extract Form, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$60.5 Billion by the end of the analysis ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Cannabidiol
... 14.5% over the analysis period 2024-2030. Hemp-sourced Cannabidiol, one of the segments analyzed in the report, is expected to record a 15.7% CAGR and reach US$14.3 Billion by the end of the analysis period. Growth ... Read More
-
CBD Gummies
... CAGR of 28.8% over the analysis period 2024-2030. Low Concentration CBD Gummies, one of the segments analyzed in the report, is expected to record a 28.2% CAGR and reach US$32.4 Billion by the end of ... Read More
-
Cannabis Extract
... CAGR of 15.6% over the analysis period 2024-2030. Cannabis Oils, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$34.1 Billion by the end of the analysis ... Read More
-
Quantum Computing in Healthcare
... 2030, growing at a CAGR of 36.9% over the analysis period 2024-2030. Quantum Computing Services, one of the segments analyzed in the report, is expected to record a 40.1% CAGR and reach US$452.4 Million by ... Read More
-
In Vivo Toxicology
... at a CAGR of 6.4% over the analysis period 2024-2030. In Vivo Toxicology Consumables, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$6.8 Billion by the ... Read More
-
Acute Heart Failure (AHF) Therapeutics
... Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$762.4 Million ... Read More
-
Fibromyalgia Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Antiepileptics, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. ... Read More
-
Lymphoma Therapeutics
... CAGR of 6.5% over the analysis period 2024-2030. Non-Hodgkin Lymphoma (NHL) Therapeutics, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$20.5 Billion by the end of ... Read More
-
Melanoma Therapeutics
... CAGR of 13.7% over the analysis period 2024-2030. Cutaneous Melanoma Therapeutics, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$4.3 Billion by the end of the ... Read More
-
Cannabis Testing
... CAGR of 13.1% over the analysis period 2024-2030. Cannabis Testing Services, one of the segments analyzed in the report, is expected to record a 14.9% CAGR and reach US$1.7 Billion by the end of the ... Read More
-
Life Science Analytics
... at a CAGR of 13.3% over the analysis period 2024-2030. Life Science Analytics Services, one of the segments analyzed in the report, is expected to record a 14.0% CAGR and reach US$44.7 Billion by the ... Read More
-
Genitourinary Drugs
... CAGR of 2.3% over the analysis period 2024-2030. Urologicals, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$10.7 Billion by the end of the analysis period. ... Read More
-
Rheumatoid Arthritis Therapeutics
... at a CAGR of 4.1% over the analysis period 2024-2030. Pharmaceuticals, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$28.0 Billion by the end of the ... Read More
-
Legal Marijuana
... CAGR of 22.3% over the analysis period 2024-2030. Marijuana Oil & Tinctures, one of the segments analyzed in the report, is expected to record a 23.4% CAGR and reach US$89.4 Billion by the end of ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC) Therapeutics, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by ... Read More
-
Cancer Therapies
... CAGR of 10.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$112.8 Billion by the end of the analysis period. ... Read More
-
Orphan Drugs
... CAGR of 12.0% over the analysis period 2024-2030. Biologic Drugs, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$308.5 Billion by the end of the analysis ... Read More
-
Acne Drugs
... CAGR of 6.9% over the analysis period 2024-2030. Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$9.6 Billion by the end of the analysis ... Read More
-
43rd Annual JP Morgan Healthcare Conference, January 13-16, 2025
... health care investment symposium in the industry. This year’s invitation-only conference provided key insights into the evolving strategies, pipeline advancements, and market trends shaping the biopharmaceutical industry, including acquisitions, innovative pipeline developments, and strategic shifts ... Read More
-
Cannabis in South Africa
... of cannabis in private spaces. In turn, the change in the legislative environment significantly increased social acceptance, which drove consumption and cultivation rates across the country. Euromonitor International's Cannabis in South Africa market report offers ... Read More
-
Cannabis in the US
... I to Schedule III, which could attract more investment and improve banking access for cannabis businesses. Euromonitor International's Cannabis in USA market report offers a comprehensive guide to the size and shape of this emerging ... Read More
Research Assistance
